---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-202601"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:57:10.920787+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rallybio receives $50M termination fee after Candid merger terminates for UCB deal

## Summary
- Candid Therapeutics terminated its merger with Rallybio to enter a Permitted Alternative Agreement with UCB S.A.
- Rallybio entitled to $50,000,000 Parent Termination Fee plus $375,000 expense reimbursement, payable by May 4, 2026.
- Rallybio, Candid and UCB entered a waiver releasing claims and waiving certain merger rights.
- Rallybio intends to withdraw its Form S-4 registration statement filed for the merger.
- The termination fee provides immediate cash, but the merger failure is a setback for Rallybio's strategic plan.

## SEC filing metadata
- accession: 0001193125-26-202601
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02, 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000119312526202601/0001193125-26-202601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000119312526202601/d19625d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-202601
- JSON: https://secwatch.observer/filing/0001193125-26-202601.json
- Plain text: https://secwatch.observer/filing/0001193125-26-202601.txt

## Source-grounded claims
- claim_id: 81da4d6c8358f31e520528be03ecbcd68e972f98
  claim: Rallybio Corp terminated Agreement and Plan of Merger and Reorganization with Candid Therapeutics, Inc. valued at $50,000,000 Parent Termination Fee (effective 2026-05-03).
  evidence_excerpt: On May 3, 2026, Candid terminated the Merger Agreement concurrently with entering into a Permitted Alternative Agreement (as defined in the Merger Agreement) with UCB S.A. (“ UCB ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000119312526202601/0001193125-26-202601-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.